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Abstract: Catheter-related bloodstream infections are a significant source of morbidity and 
mortality in the end-stage renal disease population. Although alternative accesses to undergoing 
renal replacement therapy exist, many patients begin hemodialysis with a dialysis catheter due 
to logistic and physiologic factors involved in arteriovenous fistula creation and maturation. 
Colonization of catheters via skin flora leads to the production of biofilm, which acts as a res-
ervoir for virulent bacteria. Preventative therapies center on appropriate catheter maintenance, 
infection control measures, and early removal of devices as patients transition to other access. 
Despite best efforts, when conservative measures fail to prevent infections in a high-risk popu-
lation, antimicrobial lock therapy should be considered as an option to combat catheter-related 
bloodstream infections.
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Introduction
Establishing dialysis access is often one of the most challenging aspects in the life of a 
patient requiring renal replacement therapy. A number of elements, including anatomic 
host factors, patient reluctance, and prolonged maturation time, have contributed to 
a preponderance of dialysis catheter use. National quality improvement programs, 
including the breakthrough fistula first initiative, have been ineffective and, in many 
cases, have contributed toward many patients on hemodialysis (HD) initiating renal 
replacement therapy with a catheter. Data from the Centers for Medicare and Med-
icaid Services (CMS) show a 29% overall prevalence of catheter use; however, the 
prevalence is as high as 69% in the first 6 months of dialysis and as high as 41% at 
the end of the first year.1 The prolonged maturation time inherently required in fistula 
development has contributed to a longer duration of dialysis catheter use.2 Infections are 
the second leading cause of death in patients with end-stage renal disease (ESRD).3–7 
The antecedent for the majority of these infections is catheter-related bloodstream 
infection (CRBSI).
Epidemiology of CRBSI
Over 370,000 patients undergo maintenance HD in the United States with up to 80% 
initiating treatment with a central venous catheter.8 In comparison, catheters are asso-
ciated with significantly more infections than arteriovenous (AV) fistulae or grafts 
(Table 1). A Canadian study by Taylor et al9 showed that during the first 6 months of 
dialysis, there is a high rate of bloodstream infection (BSI). In comparison to the AV 
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fistula, survival analysis yielded a relative risk of BSI of 1.47 
(95% confidence interval [CI], 0.36–5.96) for AV grafts, 8.49 
(95% CI, 3.03–23.78) for cuffed central venous catheters, 
and 9.87 (95% CI, 3.46–28.20) for noncuffed central venous 
catheters.9 The most recent data from the National Healthcare 
Safety Network (NHSN) of the Centers for Disease Control 
and Prevention (CDC) revealed a national pooled mean of 
one CRBSI per 1,000 catheter days; however, incidence rates 
reported in the literature often range much higher, ranging 
from 2.5 to 6.6 per 1,000 catheter days.3–7 The CDC reports 
that CRBSI rates have remained steady in patients with 
chronic HD with an estimated 37,000 CRBSIs occurring 
annually in 2008. Infection rates continue to be high as of 
2011; 300 hospital admissions were attributed to bacteremia 
or sepsis per 1,000 patient-years.10,11
Defining CRBSIs
CRBSIs are well defined and described in the nondialysis 
population. It was not until 2009 that the Infectious Diseases 
Society of America (IDSA) recognized the unique charac-
teristics of HD catheters. The suggested definition relies on 
obtaining a blood specimen from the dialysis catheter and an 
additional specimen from a peripheral vein.12 The existence of 
a similar colony count, differential, and time-to-sensitivity at 
both sites are the criteria for diagnosis of a CRBSI. Although 
this might be possible in a hospitalized patient, application 
of this practice to an outpatient dialysis center is impractical 
for dialysis centers in remote parts of the country. In most 
cases, the cultures are transported using mail couriers and 
cultured in laboratories that are distant from the dialysis 
unit. This scenario precludes an effective application of the 
IDSA definition in making the formal diagnosis of CRBSI. 
Also, obtaining a peripheral venous sample is often difficult 
in the ESRD population. The common practice in the HD 
population is to obtain two samples using the dialysis tubing 
during treatment at two different times. Although this is 
common practice, the evidence in support of this procedure 
is lacking and requires further study.
Pathogenesis of CRBSI
All indwelling vascular catheters are colonized by micro-
organisms within 24 hours after insertion.13 Bacteria are 
introduced into the lumen through the flora of the surround-
ing skin or the hands of health care workers during catheter 
hub manipulation.14 Bacteria migrate from the skin along 
the outside of the catheter and can seed the bloodstream. 
A Dacron cuff is incorporated close to the hub of a tunneled 
dialysis catheter for prevention of bacterial growth. The cuff 
induces an inflammatory response that creates a fibrotic 
mechanical barrier against contamination. Infections at the 
site where the catheter exits the skin at the termination of 
the tunnel are termed exit site infections. Delayed removal 
of sutures may also serve as a nidus for localized infection. 
Ascending infection from the exit site may produce puru-
lence to occur within the tunnel, necessitating removal of 
the catheter.
A major source of CRBSIs arises from bacterial biofilm 
that is produced both externally and within catheter lumen. 
Bacteria may exist in multiple forms (Figure 1).15 Indepen-
dently, bacteria may cause acute infections; collectively, they 
form sessile slime-enclosed aggregates that are resistant 
to extermination. The presence of a biofilm is not limited 
to catheter-related infections; biofilm can be seen in vivo 
in relation to nonhematogenous organs, such as pneumonia 
associated with cystic fibrosis16 as well as contaminated 
Table 1 Hospitalization and CRBSI rates by vascular access type
Rate Fistula Graft Tunneled  
catheter
Nontunneled 
catheter
Hospitalization  
(Per 100 patient-
months)
7.7 9.2 15.7 34.7
CRBSI  
(Per 100 patient-
months)
0.5 0.9 4.2 27.1
Notes: Pooled mean data from the National Health and Safety Network allows 
for quantification of the rate of infection as it relates to access type. Adapted with 
permission from John wiley and Sons from Klevens RM, edwards JR, Andrus ML, 
et al. Special Report: Dialysis surveillance report: national healthcare safety network 
(NHSN)-data summary for 2006. Semin Dial. 2007;21(1):24–28.5 Copyright © 2007 
Blackwell Publishing.5
Abbreviation: CRBSI, catheter-related bloodstream infection.
Figure 1 electron microscopy of Staphylococcus aureus magnified 2,363 times found 
on the luminal surface of an indwelling catheter.
Notes: The interdigitating substance that connects the round cocci is composed of 
polysaccharides termed “biofilm”. Photo credit Janice Carr 2005. http://phil.cdc.gov/
PHIL_Images/7485/7485_lores.jpg 
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industrial water purification equipment.17 After adhering to 
artificial surfaces, microorganisms produce extracellular 
polysaccharides that result in the formation of a matrix that 
inhibits complete eradication via intravenous antibiotics.3 
While the presence of a biofilm does not categorically provide 
resistance to anti biotics except in the case of charged antimi-
crobial agents, this slime facilitates persistence of remnant 
colonies and decreases metabolism that occurs within its 
milieu. Repeated inocula from biofilm explains persistent 
and metastatic infections that occur after administration of 
antibiotic treatment without removal or exchange of the 
catheter itself.
The majority of CBRSIs are caused by gram-positive 
organisms, such as coagulase negative staphylococci and 
Staphylococcus aureus.5 NHSN data were collected from 
461 CRBSIs and showed that 19.7% were due to S. aureus, 
while an additional 46% were due to other gram-positive 
organisms. Gram-negative rods constituted approximately 
23.2% of infections, while 1.7% of cases were due to fungal 
sources. The latter are typically seen in patients with a com-
promised immune system as well as the critically ill, who 
undergo treatment with broad-spectrum antibiotic therapy 
that alters their normal flora.18,19
S. aureus is commonly associated with significant 
morbidity and mortality. A retrospective cohort study of 
22,130 hospitalizations of dialysis patients with septicemia 
disclosed a mortality rate from S. aureus bacteremia after 
12 weeks of follow-up of 34%.20 The invasive nature of 
this pathogen is due to its ability to adhere to the surface of 
endothelial cells and undergo phagocytosis. The intracellu-
lar environment protects this organism from host defenses 
and a variety of antimicrobial agents.21 Methicillin-resistant 
S. aureus (MRSA) is particularly problematic and has 
emerged as a bacterium of interest. A report in 2005 esti-
mated the rate of invasive MRSA in dialysis patients to be 
45 per 1,000 persons compared to 0.4 infections per 1,000 
in the general population.22 Treatment of MRSA infections 
often calls for a prolonged course of antimicrobial therapy 
and removal of the catheter to provide source control and 
prevent widespread organ involvement.12
Sequelae of CBRSI may include infectious endocarditis, 
osteomyelitis, and septic arthritis as well as spinal and psoas 
abscesses. A recent retrospective cohort study conducted 
in Tokyo, Japan, showed that of 73 patients who developed 
bacteremia, 19.2% developed a metastatic infection. Sev-
eral predictive factors associated with the development of 
metastatic infection were identified including a delay in 
appropriate antimicrobial treatment of .48 hours, persistent 
fever for .72 hours after starting antibiotic treatment, and 
low C-reactive protein levels of .3 mg/dL during 2 weeks 
after the onset of bacteremia.23
S. aureus colonization via nasal carriage has received 
attention as a source of infection in patients undergoing 
HD. A study conducted in Taiwan evaluated the nasal car-
riage of MRSA and subsequent infection among dialysis 
patients, health care workers, and their families within a 
single dialysis unit.24 The investigators found that 36% of 
colonized subjects developed MRSA infections with the same 
molecular phenotype as the colonizing strain. A recent pro-
spective interventional cohort study conducted in Germany 
showed that mupirocin ointment eliminated nasal carriage 
in 26 of 34 patients.25 Of note, the remaining seven patients 
who were unable to undergo decolonization had an increase 
in all-cause mortality of .85%. It is debatable whether this 
finding indicates that resistance to prophylactic eradication is 
a predictor of disease as opposed to a reflection of the overall 
burden of comorbid diseases.
Financial impact of CRBSI
Approximately one-third of CRBSIs will require treatment in 
the hospital26 with significant financial burden. The average 
cost of each hospitalization is estimated at $22,000 USD per 
episode of bacteremia.27
While patients with chronic HD account for ,1% of 
the CMS population, they account for a disproportionate 
percentage (6.7%) of total CMS expenditures. Rates of 
hospital admissions for infection have increased by .43% 
than in 1993, consuming an ever increasing fraction of CMS 
expenditures for the ESRD program.8
Transitioning from the hospital after discharge has 
become increasingly plagued by readmission. The 2013 
USRDS annual data report cites that the dialysis population 
accounts for a disproportionate number of readmissions, 
33.3% versus 17.4% in the general population, across all 
infection domains.10 Vascular access infections resulted in 
31.1% of all-cause rehospitalization in the ESRD population. 
The high amount of antibiotic use in patients with ESRD 
confirms the infection rate in this population.
Significance of catheter insertion site
Recently, the location of catheter placement has been called 
into question. Previous recommendations from the IDSA 
have advocated avoidance of the femoral vein as an inser-
tion site. Obese patients in particular were found to be at 
risk for infection because continued sterility of the site was 
difficult to maintain. The use of jugular access may have a 
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higher risk of infection if there is a concurrent tracheostomy. 
A meta-analysis that included two randomized, controlled 
trials and eight cohort studies involving nontunneled central 
venous catheters was conducted in 2012.28 Overall, 3,230 
catheters were placed in the subclavian vein, 10,958 in the 
internal jugular, and 3,188 in the femoral vein for a total of 
113,652 catheter-days. The average CRBSI density was 2.5 
per 1,000 catheter-days (range: 0.6–7.2) regardless of loca-
tion showing no difference in the rate of CRBSIs between 
the three sites. Despite these findings not being specific to 
the dialysis population, it does call into question previously 
held beliefs regarding catheter location and is a topic for 
further prospective research.
Catheter maintenance procedures
The CDC offers a number of nonpharmacologic recommen-
dations for catheter reduction in the dialysis population.12 
Offering appropriate education to technical staff through 
training and auditing techniques ensures a vested interest on 
the part of dialysis personnel. Facilities are encouraged to 
conduct a monthly surveillance for BSIs using the NHSN of 
the CDC to calculate facility rates and actively share results 
with clinical staff members. Both monitoring for appropriate 
hand hygiene behavior and sharing the results with clinical 
staff members are encouraged. Conducting observations 
involving catheter care and assessing adherence of staff to 
aseptic technique when making connections and changing 
dressings reinforce preventative medicine techniques. Staff 
should be trained on infection control methods and evalu-
ated with regular competency assessments to maintain skill 
sets. The introduction of the care bundle, a standardized 
monitoring system for quality assurance, has been shown 
to reduce nontunneled CRBSIs in the critical care setting.29 
A similar checklist system is advocated by the CDC to allow 
for uniform exit site care (Figure 2).
Patient education regarding catheter reduction is also 
encouraged. Patients should be provided with standardized 
education regarding prevention topics including vascu-
lar access care, hand hygiene, risks related to catheter 
use, recognition of signs of infection, and instructions 
for access management when they are away from their 
dialysis unit.
Efforts should be made to reduce catheter prevalence by 
identifying barriers to permanent vascular access placement 
leading to catheter removal. A dedicated vascular access 
coordinator has been shown to facilitate this process. 
A retrospective study conducted by Dwyer et al31 showed 
that implementing a dedicated vascular access coordinator 
with a corresponding comprehensive access program led to 
an increase in the prevalent AV fistula rate from 50% to 60% 
and reduction in dialysis catheters by 50%.
Use of an alcohol-based chlorhexidine solution as the 
first-line skin antiseptic agent for central line insertion and 
during dressing changes is recommended to prevent the 
occurrence of catheter-related infections. Retrospective stud-
ies in the pediatric population have compared the use of chlo-
rhexedine versus povidone–iodine solutions and have shown 
reductions in exit site, tunnel infections, and bloodstream-
related infections with the use of chlorhexidine.32
The hub of the catheter is a known source of entry  leading 
to CRBSI. Catheter hub disinfection should involve a thor-
ough scrubbing of catheter hubs with an appropriate antisep-
tic. This technique should be performed every time a catheter 
is accessed or disconnected. Topical antibiotics have been 
shown to decrease bacteremia and exit site infection rates in 
a large meta-analysis by a ratio rate of 0.22 (CI 0.12–0.40) 
and 0.17 (CI 0.08–0.38), respectively.33 While concerns for 
the emergence of resistance to mupirocin have been raised,34 
the application of antimicrobial ointment is advocated 
by the Society of Critical Care Medicine and the IDSA.12 
Wear mask (if required) and remove dressing
Perform hand hygiene
Put on new, clean gloves 
Apply skin antiseptic
Allow skin antiseptic to dry
Do not contact exit site (after antisepsis)
Apply antimicrobial ointment that does not interact with catheter material
Apply dressing aseptically
Remove gloves
Perform hand hygiene
Figure 2 Sample checklist describing conventional catheter exit site care.
Note: Adapted from the Center for Disease Control.30 http://www.cdc.gov/dialysis/PDFs/collaborative/CL-Hemodialysis-Catheter-exit-Site-Care-508.pdf.
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The use of povidone–iodine antiseptic ointment or bacitracin/ 
gramicidin/polymyxin B ointment at the exit site after 
catheter insertion and at the end of each HD session is reco m-
mended provided the ointment does not adversely interact 
with the catheter substrate materials.
Impact of seasonality
Intensification of prophylactic efforts may be targeted at 
specific times of the year when patients are at higher risk of 
catheter-related infection and complications. An increased 
adjusted hazard ratio was seen when data from the Dialysis 
Outcomes Practice Patterns study were analyzed with regard 
to seasonality demonstrating a 46% increase in catheter-related 
septicemia during summer months when higher heat and 
humidity cause an increase in perspiration and bacterial growth 
with biofilm production.35 Protective barriers fail to remain 
adhesive during these conditions contributing to increased risk. 
Enhanced vigilance and patient education regarding catheter 
care should be emphasized during this temporal period.
Dialysis access and the elderly
Lack of alternative access is especially prevalent in the elderly 
as AV fistulas fail to develop in this patient population due to 
changes in hemodynamic and endothelial factors as well as 
atherosclerosis and calcification of surgical conduits.36 Inter-
estingly, a retrospective analysis of a cohort of elderly patients 
(mean age: 81.9 years) when compared to younger controls 
(mean age: 54.8 years) with similar microbiology, lock solution, 
catheter type, and catheter location had a significantly lower 
rate of CRBSI producing a hazard ratio of 0.33 by multivariate 
analysis.37 These results could be explained by decreased skin 
and nasal colonization rates in the elderly. Furthermore, lower 
physical activity in this age group causes less mechanical stress 
on the catheter potentiating the infection rate. Further studies 
concentrating on these proposed age-specific host factor varia-
tions may bring more light to this observation.
Antimicrobial-coated catheters
Innovations in catheter material and design to maximize 
patency and lower infection risk are ongoing. A variety of 
agents including silver, heparin, and various antibiotics have 
been incorporated into catheter composition for antimicro-
bial purposes. A large systematic review conducted in 2009 
was unable to show that antimicrobial coating, including 
chlorhexidine or silver compounds, significantly reduced 
bloodstream, exit site infections, or all-cause mortality.33 One 
randomized control trial involving 130 patients with acutely 
inserted nontunneled catheters did show an 11% reduction in 
BSIs favoring a minocycline–rifampin impregnated catheter 
versus standard controls.38 This apparent higher effective-
ness likely was a function of the shorter duration of catheter 
insertion in comparison to long-term, tunneled catheters. 
Further prospective studies in the dialysis population are 
needed to justify these devices given their added expense.
Protective barriers
A variety of novel products have been developed to minimize 
contamination of catheter access ports. The TEGO needle-
less connector system (Victus Inc., Miami, FL, USA) was 
designed to decrease catheter hub manipulation and minimize 
contamination via the use of a silicone barrier system.39 
Attachment to blood tubing creates a straight, internal fluid 
path and reinforces a closed system that avoids the need to 
cap and recap catheter ports. This apparatus was also designed 
to obviate the need for heparin-locking solution as an antico-
agulant. A retrospective analysis conducted by investigators 
for DaVita Clinical Research compared 10,652 patients uti-
lizing the TEGO connector system to 6,493 control patients 
and found a modest reduction in CRBSI rate of 10%–12% 
as defined by the initiation of antibiotics (adjusted incidence 
rate ratio 0.92, CI 0.87–0.97) or antibiotic course (incidence 
rate ratio 0.89, CI 0.84–0.95).
The Curos Disinfecting Port Protector (Ivera Medical 
Corporation, San Diego, CA, USA) is a plastic threaded 
device that contains 70% isopropyl alcohol and is designed 
to be used in conjunction with Luer-lock needleless systems. 
A quasi-experimental study conducted in a 430-bed tertiary 
referral trauma center evaluated the rate of CBRSI per 1,000 
catheter-days 12 months before and after implementation of 
these caps. The rate decreased from 1.5±0.37 to 0.88±0.62, 
yielding a .40% reduction in infection.
Prophylactic intraluminal 
antimicrobial lock therapy
Antimicrobial lock (AML) therapy involves instillation of 
a disinfectant solution into the intraluminal portion of a 
dialysis catheter between treatments to sterilize the interior 
of the catheter from biofilm. A number of studies have been 
conducted with different combinations of antimicrobial 
agents coupled with anticoagulants (Table 2). While treat-
ing an established infection has been considered appropriate 
therapy for catheter salvage, the prophylactic use of AML 
has been controversial, given concern for the emergence of 
resistant organisms. This is a major concern for the CDC 
and the primary reason for the lack of a recommendation 
for the routine use of any prophylactic antibiotic lock. Most 
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Table 2 Summary of several clinical trials utilizing antimicrobial lock solution
Study Lock solution N CD Outcome Resistance  
evaluated
Comments
Al-Hwiesh et al40 v/G/H (25/40/5,000)  
vs H (5,000)
63 14,867 13.11 vs 4.54 per 1,000 DS,  
P,0.0001
No G levels were detectable but  
,1 in 6%
Dogra et al41 G/C (40/3.13%)  
vs H (5,000)
83 5,923 4.2 vs 0.3 per 1,000 CD,  
P=0.003
No G levels were detectable in  
random sample
McIntyre et al42 G/H (5/5,000)  
vs H (5,000)
50 5,722 4 vs 0.3 per 1,000 CD,  
P=0.02
No No detectable G levels were seen
Moran et al43 G/C (0.32/4%)  
vs H (1,000)
303 72,760 0.91 vs 0.28 per 1,000 CD,  
P=0.003
Yes No change in resistance was seen;  
CRBSI rate was low in the control  
population
Nori et al6 G/C (4/3.13%)  
vs M vs H (5,000)
62 6,189 G 4 vs 0 per 1,000 CD,  
M 0.4, P=0.008
No Two different interventions were 
compared to control
Pervez et al44 G/C (18/46.7%)  
vs H (5,000)
36 4,805 2.11 vs 0.62 CD, P,0.05 No A sterile covering was used as an  
additional technique to decrease  
infection
Zhang et al45 G/H (4/5,500)  
vs H (5,500)
101 9,300 0.67 vs 0.06 per 1,000 CD,  
P=0.014
No G concentrations in the serum  
were low
Landry et al46 G/H (4/5,000) 1,410 142,365 17 vs 0.83 per 1,000 CD Yes Retrospective cohort trial that did  
report G resistance; resistance  
rates prior to lock were not  
evaluated
Moore et al47 G/C vs H (1,000) 555 71,192 1.68 vs 0.45 per 1,000 CD Yes No G resistance seen. Trend  
toward decrease was noted
Maki et al48 C/MB/P vs H 416 49,565 0.24 vs 0.82 per 1,000 CD No Antiseptic solution was used as  
opposed to an antibiotic
Broom et al49 e (70%) vs H (5,000) 49 3,614 0.85 vs 0.28 per 1,000 CD No A trend toward CRBSI reduction  
was seen but was not statistically  
significant (P=0.12)
Souweine et al50 e (60%) 2-minute  
dwell vs H
1,460 12,944 2.64 vs 3.83 No No difference in CRBSI rate or  
colonization was seen
Solomon et al51 T–C–H vs T–C  
vs H (5,000)
174 24,255 1.33 vs 1.22 vs 3.25 No Heparin was added to AML to  
decrease the need for thrombolysis
Murray et al52 T–C–H  
vs H (5,000)
565 135,446 0.69 vs 1.59 No Only Staphylococcal infections  
were investigated
Abbreviations: AML, antimicrobial lock; C, citrate; CRBSI, catheter-related bloodstream infection; CD, catheter-days; DS, dialysis sessions; e, ethanol; G, gentamicin; 
H, heparin; M, minocycline; MB, methylene blue; P, propylparaben; T, taurolidine; v, vancomycin; vs, versus.
studies evaluating efficacy of antibiotic lock have been of 
small size or of short duration, making it difficult to evalu-
ate antibiotic resistance over longer periods of time or in a 
real-world setting. A large study conducted by Landry et al 
reported a 95% reduction in CRBSIs (17–0.83 per 1,000 
catheter days) in .1,400 patients with a prophylactic gen-
tamicin/heparin lock.46 This study reported the presence of 
gentamicin-resistant organisms during 4 years of AML use. 
This eventually led to termination of the study protocol. 
A note should be made that this study lacked susceptibil-
ity data for the period before implementing the AML. This 
makes it difficult to identify whether the emergence of gen-
tamicin resistance patterns changed after initiation of the 
lock as similar patterns could have existed before AML use. 
A randomized, controlled trial using the same prophylac-
tic, low-dose citrate gentamicin formulation found stable 
gentamicin susceptibility patterns over the 5-year course of the 
study in both treatment groups.43 A prospective, observational 
cohort study in 555 patients conducted over a 3-year period 
showed a 73% reduction in CRBSI after a gentamicin citrate 
locking solution was instituted.47 A unique feature of this study 
was the decrease in mortality after AML was initiated with 
an adjusted hazard ratio of 0.32 (CI 0.14–0.75). The rate of 
gentamicin-resistant organisms actually decreased over the 
course of the study. It was hypothesized that these findings 
are related to the lower dose of gentamicin used in the lock 
solution and the use of citrate as opposed to heparin, which 
has been shown to promote biofilm formation.53,54
The controversy regarding antibiotic resistance in AML 
has led to the use of other antiseptic solutions that do not 
contain antibiotics. Taurolidine, an agent that directly affects 
bacterial cell walls, has had promising results in the reduction 
of CRBSIs. While it lacks the stigma of antibiotic resistance, 
this taurine-like molecule has been linked to an increased 
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need for thrombolytic therapy due to occlusion problems. 
The incorporation of heparin within the AML solution was 
shown to obviate this issue.48,51,55
Ethanol has been proposed as an attractive option for 
AML as it is relatively inexpensive and is effective against a 
wide variety of microorganisms including fungi. A prospec-
tive study involving a high-risk population of 64 patients 
undergoing chemotherapy via tunneled catheters showed 
a decrease in infections by four-fold, three in the ethanol 
group versus eleven in the control group, when ethanol was 
used as daily prophylaxis.56 Once weekly ethanol instilled for 
48 hours in patients with HD was associated with an insignifi-
cant 67% decrease in CBRSI.49 Shorter dwell times for this 
agent have been postulated as prolonged ethanol exposure 
may lead to catheter dysfunction. A French study involving 
critically ill patients with nontunneled catheters compared a 
2-minute ethanol dwell time to heparinized controls and did 
not show a significant difference in outcome.50,57 The authors 
suggested that the short interval of catheter use likely con-
tributed to the results as previous positive studies involved 
longer durations of catheter use.
Conclusion
A host of resources have been dedicated to combating CRBSIs 
in patients with HD. Notwithstanding, CBRSIs remain a 
considerable problem that plague the ESRD community and 
health care providers due to the consequences of the disease 
and mortality effects. Early efforts must be directed toward 
preventative care emphasizing placement of other vascular 
accesses or initiating an alternative dialysis modality, such 
as timely peritoneal dialysis (PD) to avert HD catheter place-
ment before it becomes necessary. Initiating PD acutely via 
“urgent start PD” programs has been shown to be a safe 
alternative to HD in patients without an established AV fistula 
or graft.58 Should no options exist outside of HD catheter 
placement, proper catheter care and infection control pro-
cedures are the first step in preventing infections. Auditing 
and educating both patients and dialysis unit personnel are 
of the utmost importance. Lastly, AML therapy should be 
considered in high-risk groups who have utilized all other 
conservative measures to prevent infection.
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